Takuro Kameda

2.7k total citations
30 papers, 393 citations indexed

About

Takuro Kameda is a scholar working on Immunology, Genetics and Molecular Biology. According to data from OpenAlex, Takuro Kameda has authored 30 papers receiving a total of 393 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Immunology, 12 papers in Genetics and 11 papers in Molecular Biology. Recurrent topics in Takuro Kameda's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (12 papers), T-cell and Retrovirus Studies (11 papers) and Vector-Borne Animal Diseases (8 papers). Takuro Kameda is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (12 papers), T-cell and Retrovirus Studies (11 papers) and Vector-Borne Animal Diseases (8 papers). Takuro Kameda collaborates with scholars based in Japan and Indonesia. Takuro Kameda's co-authors include Kazuya Shimoda, Kotaro Shide, Yoko Kubuki, Haruko Shimoda, Tomonori Hidaka, Kenji Nagata, Satoru Hasuike, Tadashi Matsuda, Ayako Kamiunten and Masaaki Sekine and has published in prestigious journals such as Blood, Biochemical and Biophysical Research Communications and Leukemia.

In The Last Decade

Takuro Kameda

28 papers receiving 385 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Takuro Kameda Japan 10 217 213 200 77 63 30 393
Anna Leszl Italy 13 68 0.3× 230 1.1× 186 0.9× 34 0.4× 58 0.9× 34 506
Kim-Hien T. Dao United States 10 190 0.9× 309 1.5× 303 1.5× 80 1.0× 54 0.9× 13 566
R Hehlmann Germany 10 132 0.6× 149 0.7× 220 1.1× 84 1.1× 81 1.3× 14 395
Shady Adnan Awad Finland 11 124 0.6× 81 0.4× 174 0.9× 46 0.6× 65 1.0× 23 299
Jastinder Sohal United Kingdom 11 200 0.9× 408 1.9× 452 2.3× 173 2.2× 65 1.0× 19 772
Ana Aventín Spain 11 148 0.7× 350 1.6× 339 1.7× 56 0.7× 51 0.8× 18 610
Paul Sinclair United Kingdom 16 285 1.3× 306 1.4× 474 2.4× 153 2.0× 57 0.9× 24 827
Jon McMahel United States 10 99 0.5× 175 0.8× 281 1.4× 15 0.2× 120 1.9× 10 487
CA Westbrook United States 8 165 0.8× 106 0.5× 338 1.7× 65 0.8× 48 0.8× 10 431
Lemlem Alemu United States 12 82 0.4× 228 1.1× 220 1.1× 50 0.6× 57 0.9× 25 451

Countries citing papers authored by Takuro Kameda

Since Specialization
Citations

This map shows the geographic impact of Takuro Kameda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Takuro Kameda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Takuro Kameda more than expected).

Fields of papers citing papers by Takuro Kameda

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Takuro Kameda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Takuro Kameda. The network helps show where Takuro Kameda may publish in the future.

Co-authorship network of co-authors of Takuro Kameda

This figure shows the co-authorship network connecting the top 25 collaborators of Takuro Kameda. A scholar is included among the top collaborators of Takuro Kameda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Takuro Kameda. Takuro Kameda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Morishita, Daisuke, Akio Mizutani, Yasuyoshi Arikawa, et al.. (2022). Preclinical Translational Research Suggests a Clinical Trial Strategy for a Novel MALT1 Inhibitor ONO-7018/CTX-177 Against Malignant Lymphomas. Blood. 140(Supplement 1). 8874–8875. 1 indexed citations
2.
Permatasari, Happy Kurnia, Shingo Nakahata, Tomonaga Ichikawa, et al.. (2022). Oncogenic isoform switch of tumor suppressor BCL11B in adult T-cell leukemia/lymphoma. Experimental Hematology. 111. 41–49. 1 indexed citations
3.
Shide, Kotaro, Takuro Kameda, Ayako Kamiunten, et al.. (2020). Calreticulin haploinsufficiency augments stem cell activity and is required for onset of myeloproliferative neoplasms. Blood. 136(1). 106–118. 10 indexed citations
4.
Miike, Tadashi, Hiroshi Kawakami, Takuro Kameda, et al.. (2020). Clinical characteristics of adult T-cell leukemia/lymphoma infiltration in the gastrointestinal tract. BMC Gastroenterology. 20(1). 298–298. 2 indexed citations
5.
Kameda, Takuro, Kotaro Shide, Ayako Kamiunten, et al.. (2020). CARD11 Mutation Induces Oligoclonal Expansion of T-Cells, and Accelerates ATL Development in Combination with HBZ. Blood. 136(Supplement 1). 17–18. 2 indexed citations
6.
Akizuki, Keiichi, Masaaki Sekine, Yasunori Kogure, et al.. (2020). TP53 and PTEN mutations were shared in concurrent germ cell tumor and acute megakaryoblastic leukemia. BMC Cancer. 20(1). 5–5. 17 indexed citations
7.
Shide, Kotaro, Takuro Kameda, Ayako Kamiunten, et al.. (2020). Neoplastic fibrocytes play an essential role in bone marrow fibrosis in Jak2V617F-induced primary myelofibrosis mice. Leukemia. 35(2). 454–467. 29 indexed citations
8.
Shide, Kotaro, Ayako Kamiunten, Takuro Kameda, et al.. (2019). Monocyte-derived fibrocytes elimination had little contribution on liver fibrosis. Hepatobiliary & pancreatic diseases international. 18(4). 348–353. 3 indexed citations
9.
10.
Shide, Kotaro, Takuro Kameda, Masaaki Sekine, et al.. (2017). Loss of Tyrosine Kinase 2 Does Not Affect the Severity of Jak2V617F-induced Murine Myeloproliferative Neoplasm. Anticancer Research. 37(7). 3841–3847. 1 indexed citations
11.
Nakahata, Shingo, Tomonaga Ichikawa, Akira Kitanaka, et al.. (2017). Development of a complete human IgG monoclonal antibody to transferrin receptor 1 targeted for adult T-cell leukemia/lymphoma. Biochemical and Biophysical Research Communications. 485(1). 144–151. 30 indexed citations
12.
Sekine, Masaaki, Yoko Kubuki, Takuro Kameda, et al.. (2017). Effects of mogamulizumab in adult T‐cell leukemia/lymphoma in clinical practice. European Journal Of Haematology. 98(5). 501–507. 17 indexed citations
13.
Sekine, Masaaki, Masaki Takeuchi, Seiichi Sato, et al.. (2016). Mogamulizumab for ATLL in Clinical Practice. Blood. 128(22). 2998–2998. 1 indexed citations
14.
Kameda, Takuro, Kotaro Shide, Ayako Kamiunten, et al.. (2015). Gene expression profiling of loss of TET2 and/or JAK2V617F mutant hematopoietic stem cells from mouse models of myeloproliferative neoplasms. Genomics Data. 4. 102–108. 3 indexed citations
15.
Shimoda, Kazuya, Kotaro Shide, Takuro Kameda, et al.. (2015). TET2 Mutation in Adult T-Cell Leukemia/Lymphoma. Journal of Clinical and Experimental Hematopathology. 55(3). 145–149. 16 indexed citations
16.
Kameda, Takuro, Kotaro Shide, & Kazuya Shimoda. (2015). [Genetic and epigenetic abnormalities in myeloproliferative neoplasms].. PubMed. 56(6). 614–22. 1 indexed citations
17.
Shide, Kotaro, Takuro Kameda, Haruko Shimoda, et al.. (2012). TET2 is essential for survival and hematopoietic stem cell homeostasis. Leukemia. 26(10). 2216–2223. 64 indexed citations
18.
Kameda, Takuro, Kotaro Shide, Haruko Shimoda, et al.. (2010). Absence of gain-of-function JAK1 and JAK3 mutations in adult T cell leukemia/lymphoma. International Journal of Hematology. 92(2). 320–325. 10 indexed citations
19.
Shimoda, Haruko, Kotaro Shide, Takuro Kameda, Takuya Matsunaga, & Kazuya Shimoda. (2010). Tyrosine kinase 2 interacts with the proapoptotic protein Siva-1 and augments its apoptotic functions. Biochemical and Biophysical Research Communications. 400(2). 252–257. 10 indexed citations
20.
Shide, Kotaro, Haruko Shimoda, Kennosuke Karube, et al.. (2007). Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F. Leukemia. 22(1). 87–95. 133 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anna Leszl Breakdown of academic impact, for papers by Kim-Hien T. Dao Breakdown of academic impact, for papers by R Hehlmann Breakdown of academic impact, for papers by Shady Adnan Awad Breakdown of academic impact, for papers by Jastinder Sohal Breakdown of academic impact, for papers by Ana Aventín Breakdown of academic impact, for papers by Paul Sinclair Breakdown of academic impact, for papers by Jon McMahel Breakdown of academic impact, for papers by CA Westbrook Breakdown of academic impact, for papers by Lemlem Alemu
Rankless by CCL
2026